CN1273588A - 用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列 - Google Patents

用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列 Download PDF

Info

Publication number
CN1273588A
CN1273588A CN98808996A CN98808996A CN1273588A CN 1273588 A CN1273588 A CN 1273588A CN 98808996 A CN98808996 A CN 98808996A CN 98808996 A CN98808996 A CN 98808996A CN 1273588 A CN1273588 A CN 1273588A
Authority
CN
China
Prior art keywords
toxin
antibody
sequence
mentioning
aminoacid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98808996A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托夫·冯·艾克尔－施特赖伯
麦克尔·默斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1273588A publication Critical patent/CN1273588A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN98808996A 1997-09-10 1998-09-10 用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列 Pending CN1273588A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE19739685.2 1997-09-10

Publications (1)

Publication Number Publication Date
CN1273588A true CN1273588A (zh) 2000-11-15

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98808996A Pending CN1273588A (zh) 1997-09-10 1998-09-10 用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列

Country Status (11)

Country Link
US (2) US6667035B1 (enExample)
EP (1) EP0994904B1 (enExample)
JP (1) JP4318398B2 (enExample)
CN (1) CN1273588A (enExample)
AT (1) ATE254139T1 (enExample)
AU (1) AU9742698A (enExample)
BR (1) BR9815367A (enExample)
CA (1) CA2303202C (enExample)
DE (2) DE19739685A1 (enExample)
ES (1) ES2210832T3 (enExample)
WO (1) WO1999012971A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482331A (zh) * 2009-07-27 2012-05-30 碧奥迪克斯有限公司 用于检测和鉴别样品中变异艰难梭菌菌株的方法
CN107022532A (zh) * 2011-04-22 2017-08-08 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1358331A2 (en) * 2001-02-09 2003-11-05 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
EP1609491B1 (en) * 2004-06-16 2008-02-06 Straumann Holding AG Barrier membrane
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
AU2005321974B2 (en) * 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CN105017423B (zh) * 2005-08-11 2019-06-04 阿皮·马托西安-罗杰斯 用于自身免疫性疾病治疗和诊断的TCR-V-β相关肽
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) * 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012118693A1 (en) * 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
SG11201400916XA (en) 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
WO2013130981A1 (en) * 2012-03-02 2013-09-06 Regeneron Pharmaceuticals, Inc. Human antibodies to clostridium difficile toxins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
DE3471661D1 (en) 1984-03-02 1988-07-07 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
CZ296806B6 (cs) 1994-10-24 2006-06-14 Allergan, Inc. Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482331A (zh) * 2009-07-27 2012-05-30 碧奥迪克斯有限公司 用于检测和鉴别样品中变异艰难梭菌菌株的方法
CN102482331B (zh) * 2009-07-27 2014-12-24 碧奥迪克斯有限公司 用于检测和鉴别样品中变异艰难梭菌菌株的方法
CN107022532A (zh) * 2011-04-22 2017-08-08 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
CN107022532B (zh) * 2011-04-22 2021-05-04 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法

Also Published As

Publication number Publication date
AU9742698A (en) 1999-03-29
JP2001515920A (ja) 2001-09-25
DE59810172D1 (de) 2003-12-18
CA2303202C (en) 2010-04-27
WO1999012971A2 (de) 1999-03-18
US20040137601A1 (en) 2004-07-15
DE19739685A1 (de) 1999-03-11
EP0994904B1 (de) 2003-11-12
WO1999012971A3 (de) 1999-07-22
ATE254139T1 (de) 2003-11-15
CA2303202A1 (en) 1999-03-18
JP4318398B2 (ja) 2009-08-19
BR9815367A (pt) 2001-11-06
US7151159B2 (en) 2006-12-19
ES2210832T3 (es) 2004-07-01
EP0994904A2 (de) 2000-04-26
US6667035B1 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
CN1273588A (zh) 用于治疗和预防多毒素梭状芽胞杆菌毒素导致的疾病的氨基酸序列
CN1305905C (zh) 人源化抗体及其制备方法
CN1187374C (zh) 人源化的特异于人4－1bb的抗体和含有它的药物组合物
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1222162A (zh) 突变的无激活作用的IgG2结构域和插入该结构域的抗CD3抗体
CN1087681A (zh) 具有抗人体内病原菌感染的被动免疫力的新抗体
CN1800359A (zh) 卡他摩拉克菌外膜蛋白－106多肽及其基因序列和用途
CN1227607A (zh) 与α4β7整合蛋白相作用的人化免疫球蛋白
CN1263556A (zh) 抗gpiib/iiia重组抗体
CN1341124A (zh) 抗cd3免疫毒素及其治疗用途
CN1308676A (zh) 抗cd23抗体、抗cd23抗体衍生物及其治疗性应用
CN1277632A (zh) 天然人源化抗体
CN1235639A (zh) 重新构建的人抗hm1.24抗体
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1738646A (zh) 可用来抵御并治疗hiv感染的去免疫化单克隆抗体
CN1077991A (zh) 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
CN1898267A (zh) 修饰的抗cd52抗体
CN1422333A (zh) 诱导细胞凋亡的多肽
CN101054582A (zh) A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
CN1212016A (zh) 重组的核糖核酸酶蛋白质
CN1078250C (zh) 抗免疫球蛋白等模式标本的重整形单克隆抗体
CN1225479C (zh) 肿瘤坏死因子抗体，其制备方法以及药物组合物
CN1788018A (zh) 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体
CN1566341A (zh) 一种用于抗体改形的体外分子定向进化方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication